Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
9 Results for "
obstructive sleep apnea
" in MedChemExpress (MCE) Product Catalog:
Products (9)
9 Results for "obstructive sleep apnea" in MCE Product Catalog:
Cat. No.: HY-159639
CAS No.: 2642235-06-9
Target:
Research Areas:
BAY-2925976 is an α2C adrenergic receptor (ARα2C) antagonist that can be used for the study of obstructive sleep apnea (OSA) .
Cat. No.: HY-B0267C
CAS No.: 119618-21-2
Synonyms: Aroxybutynin
Target:
Research Areas:
(R)-Oxybutynin (Aroxybutynin), an enantiomer of Oxybutynin, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin exhibits antispasmodic and anticholinergic activities, and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin can be used in the research of urinary incontinence caused by neurogenic bladder dysfunction .
Cat. No.: HY-B0267B
CAS No.: 1207344-05-5
Synonyms: Aroxybutynin hydrochloride
Target:
Research Areas:
(R)-Oxybutynin hydrochloride (Aroxybutynin hydrochloride), an enantiomer of Oxybutynin hydrochloride, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin hydrochloride exhibits antispasmodic and anticholinergic activities, and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin hydrochloride can be used in the research of urinary incontinence caused by neurogenic bladder dysfunction .
Target:
Research Areas:
Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1).
Cat. No.: HY-123836
CAS No.: 936626-07-2
Target:
Research Areas:
MK-7288 is a histamine H3 receptor inverse agonist. MK-7288 can prolong sleep latency in the Maintain Wake Test (MWT). MK-7288 can be used in research on obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS) .
Cat. No.: HY-B0267BS
Target:
Research Areas:
Oxybutynin-d5 hydrochloride is the d5-labeled (R)-Oxybutynin hydrochloride (HY-B0267B). (R)-Oxybutynin hydrochloride (Aroxybutynin hydrochloride), an enantiomer of Oxybutynin hydrochloride, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin hydrochloride exhibits antispasmodic and anticholinergic activities, and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin hydrochloride can be used in the research of urinary incontinence caused by neurogenic bladder dysfunction .
Cat. No.: HY-L087
3,695 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.
MCE Anti-Obesity Compound Library owns a unique collection of 3,695 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.
Cat. No.: HY-184098
CAS No.: 2770252-94-1
Synonyms: Lomasemtivum
Target:
Research Areas:
Lomasemtiv (Lomasemtivum) is a Troponin activator. Lomasemtiv activates skeletal muscle myofibrils. Lomasemtiv is applicable to sarcopenia research .
Cat. No.: HY-186050
CAS No.: 3105300-99-7
Target:
Research Areas:
GIPR antagonist 2 is a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist with an IC50 of 7.2 nM in CHO-K1 cells. GIPR antagonist 2 can be used in research related to diseases such as obesity, type 2 diabetes, non-alcoholic fatty liver disease, and atherosclerosis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
